Solesis Acquires Polyzen
New York, NY— Solesis, an operating company of Altaris, LLC (collectively with its affiliates, “Altaris”), announced today that it has completed the acquisition of Polyzen, LLC. Polyzen is a leading developer and manufacturer of polymer-based films, coatings, components and assemblies for the medical device and biopharmaceutical industries. Polyzen is based in Apex, NC. Following the acquisition, Polyzen will operate as a subsidiary of Solesis.
Solesis is an advanced biomaterials company that develops, manufactures and sells critical components and technologies for customers in the medical device, biopharmaceutical and life sciences industries. The acquisition of Polyzen expands Solesis’ capabilities to include polymer-based coating and film technologies, which have complementary applications across Solesis’ existing customer base and end markets, including implantable medical devices, bioprocessing, drug delivery and cell and gene therapy. Solesis is headquartered in Telford, PA with manufacturing facilities in Pennsylvania and North Carolina. Altaris acquired a majority ownership interest in Solesis as part of a corporate partnership transaction with Michelin in 2021.
Cleary Gottlieb acted as legal counsel to Solesis. Polyzen was advised by Piper Sandler & Co. and Bagchi Law.
Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Since inception in 2003, Altaris has invested in 49 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages over $5.0 billion of equity capital.